Advaxis cancer drug gets Orphan designation

The FDA designates Advaxis' (ADXS +6.8%) ADXS-cHER2 an Orphan Drug for the treatment of osteosarcoma. The drug is an immunotherapy that targets the HER2 receptor which is overexpressed in certain cancers. The company plans to initiate a clinical development program in pediatric osteosarcoma, a rare cancer affecting ~400 children and teens in the U.S. each year.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs